ROSEN, Leading Investor Counsel, Encourages Spero Therapeutics, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - SPRONewsfile Corp • 06/06/22
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Spero Therapeutics, Inc. (SPRO) InvestorsBusiness Wire • 06/06/22
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Spero Therapeutics, Inc. (SPRO) InvestorsBusiness Wire • 06/06/22
ROSEN, National Trial Lawyers, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SPRONewsfile Corp • 06/04/22
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Spero Therapeutics, Inc. (SPRO) on Behalf of InvestorsBusiness Wire • 06/03/22
Bronstein, Gewirtz & Grossman, LLC Notifies Spero Therapeutics, Inc. (SPRO) Shareholders of Class Action and Encourages Investors to Contact the FirmBusiness Wire • 06/03/22
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Spero Therapeutics, Inc. (SPRO) on Behalf of InvestorsBusiness Wire • 06/03/22
SPRO INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Spero Therapeutics, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - SPROPRNewsWire • 06/02/22
The Law Offices of Frank R. Cruz Announces Investigation of Spero Therapeutics, Inc. (SPRO) on Behalf of InvestorsBusiness Wire • 06/02/22
SPERO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Spero Therapeutics, Inc. and Encourages Investors to Contact the FirmBusiness Wire • 06/02/22
Bronstein, Gewirtz & Grossman, LLC Notifies Spero Therapeutics, Inc. (SPRO) Shareholders of Class Action and Encourages Investors to Contact the FirmPRNewsWire • 06/01/22
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Spero Therapeutics, Inc. (SPRO)Business Wire • 05/31/22
Shareholder Alert: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Spero Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SPRONewsfile Corp • 05/28/22
EQUITY ALERT: Rosen Law Firm Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – SPROBusiness Wire • 05/27/22
Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/17/22
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/16/22
Spero Therapeutics Announces First Quarter 2022 Operating Results and Provides Business UpdateGlobeNewsWire • 05/16/22
Spero Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results on Monday, May 16, 2022GlobeNewsWire • 05/09/22
Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage PipelineGlobeNewsWire • 05/03/22
Earnings Preview: Spero Therapeutics, Inc. (SPRO) Q1 Earnings Expected to DeclineZacks Investment Research • 04/28/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spero Therapeutics, Inc. - SPROPRNewsWire • 04/25/22
Spero Therapeutics to Present Data at the 32nd European Congress of Clinical Microbiology and Infectious DiseasesGlobeNewsWire • 04/21/22
